Evidence map›Paper›PMID 39257976›Full record

ArticleResearch square2024

KLF2 determines the susceptibility of T cells to immunoregulatory NK cells.

Stephen Waggoner, Andrew Cox, Laura Canaday, Alexander Katko, Harrison Feldman, Kathrynne Warrick, Anastassia Tselikova, Harsha Seelamneni, Krishna Roskin

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stephen WaggonerCincinnati Children's Hospital Medical Center.ORCID 0000-0001-9658-2874
Andrew CoxCincinnati Children's Hospital Medical Center.
Laura CanadayCincinnati Children's Hospital Medical Center.ORCID 0000-0002-8053-2431
Alexander KatkoCincinnati Children's Hospital Medical Center.
Harrison FeldmanCincinnati Children's Hospital Medical Center.ORCID 0000-0002-3281-2535
Kathrynne WarrickCincinnati Children's Hospital Medical Center.ORCID 0000-0002-9385-3365
Anastassia TselikovaUCLA.
Harsha SeelamneniCincinnati Children's Hospital Medical Center.
Krishna RoskinCincinnati Children's Hospital Medical Center.ORCID 0000-0002-5864-5093

Funding

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2M
Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Alexander Miethke · 2007 to 2026
$24.4M
Tissue Repository CoreP30AR070549 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI Grant Sanford Schulert · 2016 to 2026
$7.7M
Medical Scientist Training ProgramT32GM063483 · NIGMS · UNIVERSITY OF CINCINNATI · PI KHURANA HERSHEY, GURJIT K. · 2002 to 2022
$6.7M
Targeting natural killer cells to enhance HIV vaccine responsesR01AI148080 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI WAGGONER, STEPHEN N. · 2019 to 2023
$3.3M
Blocking granzyme-mediated immune suppression to enhance HIV vaccine efficacyR01AI176519 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI Vijayakumar Velu, Stephen N. Waggoner · 2023 to 2026
$2.8M
Vaccinology Training ProgramT32AI165396 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI Robert Wilson Frenck, PAUL W. SPEARMAN · 2022 to 2026
$1.4M
NIAID NIH HHS R01 AI148080NIAID NIH HHS R01 AI176519NIAID NIH HHS T32 AI165396NIAID NIH HHS UM1 AI148684NIAMS NIH HHS P30 AR070549NICHD NIH HHS K12 HD000850NIDDK NIH HHS P30 DK078392NIGMS NIH HHS T32 GM063483
6 · The paper itself

Abstract

Natural killer (NK) cells suppress cellular and humoral immune responses via killing of T cells, resulting in diminished vaccine responses in mice and humans. Efforts to overcome this roadblock and achieve optimal immunity require an improved understanding of the molecular mediators facilitating NK cell-targeting of discrete subsets of CD4 T cells. We employed single-cell forensic victimology and CRISPR-Cas9 editing to delineate a transcriptional program uniquely responsible for the susceptibility of a subpopulation of CD4 T cells to perforin-dependent immunoregulation by NK cells. The unique vulnerability of these CD4 T cells relative to other subsets of CD4 T cells was not associated with a pattern of NK-cell-receptor ligand expression that would favor activation of NK cells. Instead, susceptible CD4 T cells were skewed toward follicular helper T cell (Tfh) differentiation and exhibited intermediate expression of Klf2 and a related suite of KLF2-target genes (e.g. S1pr1) involved in cell migration and spatial positioning. NK-cell dependent suppression of the subset of Tfh exhibiting intermediate expression of KLF2 and S1PR1 was confirmed with single-cell proteomics. CRISPR targeting of KLF2 in CD4 T cells prevented suppression by NK cells. Thus, KLF2 regulation of spatial positioning of T cells is a key determinant of NK-cell immunoregulatory function and a possible target for strategies to enhance vaccine efficacy.

Indexed as

immune suppressioninnate lymphoid cellmigrationvaccine

Identifiers

PMID39257976
PMCPMC11384801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.